She Ain't Pretty...Not worth anymore than it was pre- 2008 aquisition rampage.
Rewind, and shed all the assets purchased with credit and what
do you have a highly indebted company with a poor public image.
Sale of all assets aquired are unlikely to yield valuation above debt
and considering managements strategy was focused on aquisition
and not organic growth the value of these companies are in many
cases less than pre VRX aquisition as the R&D $ was not spent
to grow or enhance the value of individual aquisitions.
Stock traded at around $13 in 2008 and can't imagine it being worth
anymore now and quite possibly considerably less.
They will have a difficult time moving forward as a "traditional" pharma;
Let the personal attacks commence